Impact Of Electronic Health Record Interface Design On Unsafe Prescribing Of Ciclosporin, Tacrolimus and Diltiazem: A Cohort Study In English NHS Primary Care-Reference-Cited by-同舟云学术

Impact Of Electronic Health Record Interface Design On Unsafe Prescribing Of Ciclosporin, Tacrolimus and Diltiazem: A Cohort Study In English NHS Primary Care

Published:2019-11-12 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

MacKenna Brian^ORCID,Bacon Seb^ORCID,Walker Alex J^ORCID,Curtis Helen J^ORCID,Croker Richard^ORCID,Goldacre Ben^ORCID

Abstract

AbstractBackgroundIn England, national safety guidance recommends that ciclosporin, tacrolimus and diltiazem are prescribed by brand name due to their narrow therapeutic windows and, in the case of tacrolimus, to reduce the chance of organ transplantation rejection. Various small studies have shown that changes to electronic health records (EHR) interface can affect prescribing choices.ObjectivesOur objectives were to assess variation by EHR system in breaches of safety guidance around prescribing of ciclosporin, tacrolimus and diltiazem; and to conduct user-interface research into the causes of such breaches.MethodsWe carried out a retrospective cohort study using prescribing data in English primary care. Participants were English general practices and their respective electronic health records. The main outcome measures were (1) variation in ratio of breaching / adherent prescribing all practices (2) description of observations of EHR usage.ResultsA total of 2,575,411 prescriptions were issued in 2018 for ciclosporin, tacrolimus and diltiazem (over 60mg); of these, 316,119 prescriptions breached NHS guidance (12.3%). Breaches were most common amongst users of the EMIS EHR (in 23.2% of ciclosporin & tacrolimus prescriptions, and 22.7% of diltiazem prescriptions); but breaches were observed in all EHRs.ConclusionDesign choices in EHR strongly influence safe prescribing of ciclosporin, tacrolimus and diltiazem; and breaches are prevalent in general practices in England. We recommend that all EHR vendors review their systems to increase safe prescribing of these medicines in line with national guidance. Almost all clinical practice is now mediated through an EHR system: further quantitative research into the effect of EHR design on clinical practice is long overdue.

Publisher

Cold Spring Harbor Laboratory

Reference31 articles.

1. NHS Digital. Prescription Cost Analysis - England, 2018. https://digital.nhs.uk/data-and-information/publications/statistical/prescription-cost-analysis/2018 (accessed 8 Apr 2019).

2. NHS Digital. Deployment and utilisation progress data. https://digital.nhs.uk/data-and-information/data-tools-and-services/tools-for-accessing-data/deployment-and-utilisation-progress-data (accessed 2 Jul 2019).

3. NHS Digital. GPSoC services. https://digital.nhs.uk/services/gp-systems-of-choice/gpsoc-services (accessed 8 Apr 2019).

4. MacKenna B. Ghost branded generics: Why does the cost of generic atorvastatin vary? EBM DataLab. 2018. https://ebmdatalab.net/ghost-branded-generics-why-does-the-cost-of-generic-atorvastatin-vary%ef%bb%bf/ (accessed 8 Apr 2019).

5. Medicines and Healthcare products Regulatory Agency (MHRA). Ciclosporin: must be prescribed and dispensed by brand name. https://webarchive.nationalarchives.gov.uk/20101116143818/ http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087726 (accessed 8 Apr 2019).